Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Accounts Payables: 2010-2024

Historic Accounts Payables for Anika Therapeutics (ANIK) over the last 15 years, with Dec 2024 value amounting to $5.6 million.

  • Anika Therapeutics' Accounts Payables fell 30.46% to $4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.7 million, marking a year-over-year decrease of 30.46%. This contributed to the annual value of $5.6 million for FY2024, which is 9.32% down from last year.
  • Per Anika Therapeutics' latest filing, its Accounts Payables stood at $5.6 million for FY2024, which was down 9.32% from $6.2 million recorded in FY2023.
  • In the past 5 years, Anika Therapeutics' Accounts Payables ranged from a high of $9.1 million in FY2022 and a low of $5.6 million during FY2024.
  • Over the past 3 years, Anika Therapeutics' median Accounts Payables value was $6.2 million (recorded in 2023), while the average stood at $7.0 million.
  • In the last 5 years, Anika Therapeutics' Accounts Payables skyrocketed by 134.45% in 2020 and then plummeted by 31.74% in 2023.
  • Anika Therapeutics' Accounts Payables (MRY) stood at $9.0 million in 2020, then decreased by 15.04% to $7.6 million in 2021, then rose by 18.88% to $9.1 million in 2022, then plummeted by 31.74% to $6.2 million in 2023, then fell by 9.32% to $5.6 million in 2024.
  • Its Accounts Payables stands at $5.6 million for FY2024, versus $6.2 million for FY2023 and $9.1 million for FY2022.